Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idelalisib in Japanese Subjects with iNHL or CLL
NCT02242045Phase 1Completed
- Sponsor
- Gilead Sciences
- Start
- Oct 2014
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of idelalisib in B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL), sponsored by Gilead Sciences. Primary endpoints: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) Within 28 Days, Percentage of Participants Experiencing TEAEs Related to Idelalisib Within 28 Days and 3 more. Started Oct 2014; status: completed.
02
Drugs
idelalisib
03
Conditions
B-cell non-Hodgkin lymphomachronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT02242045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02242045.